| Hepatitis | News
Liver cirrhosis: causes and immunoglobulin levels

Liver cirrhosis can have different underlying causes, making accurate diagnosis essential for choosing the right treatment. A study explores how IgG, IgA, and IgM immunoglobulin levels can help distinguish between these causes and support diagnosis without the need for a liver biopsy.

| Diseases | Hepatitis B | News
Prognostic analytical markers for Hepatitis B

Viral load and transaminase levels are important indicators for assessing the prognosis of chronic hepatitis B. A study published in The Lancet found that an HBV DNA level above 2,000 IU/mL and elevated transaminases are associated with a higher risk of advanced liver disease. These markers can help guide patient monitoring and individualized treatment decisions.

| Hepatitis B | News | Treatments
New treatment for hepatitis B with Bepirovirsen

A study published in The New England Journal of Medicine shows that Bepirovirsen significantly increases the likelihood of achieving a functional cure for chronic hepatitis B.

| Hepatitis B | News | Treatments
Study of a new drug for the treatment of Hepatitis B

A study suggests GST-HG141 may become an effective new hepatitis B treatment for patients with incomplete response to current antiviral therapies.

| Fatty liver | News | Treatments
Diuretic drug: Spironolactone and fatty liver

A study shows spironolactone reduces fatty liver risk in patients with hypertension, lowering liver fat accumulation and slowing fibrosis progression.

| Autoinmune hepatitis | Diseases | News
Higher risk of autoimmune hepatitis after age 65

Autoimmune hepatitis incidence has increased notably in older adults, with higher prevalence and better treatment response, often presenting with milder symptoms.

| Health | News
New drugs for weight loss

Orforglipron, an oral GLP-1 small molecule, shows significant weight loss results and may become an alternative to injectable drugs like Ozempic or Wegovy.

| Hepatitis B | News | Treatments
New treatment for Hepatitis B

Hydronidone has demonstrated significant reversal of liver fibrosis in patients with chronic hepatitis B, offering a potential new therapeutic option.

| Fatty liver | News | Treatments
Controlled metabolic accelerator: new drug for treating fatty liver disease

HU6 is a novel oral drug that reduces liver fat and body weight through controlled metabolic acceleration, showing promising results in clinical trials compared to placebo.

| Diseases | Fatty liver | News
Fatty liver disease and alcohol tolerance

A large study shows that daily alcohol consumption, even in small amounts, worsens liver fibrosis in patients with metabolic liver disease.

Clínica FEHV
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

About Us

The Foundation for the Study of Viral Hepatitis is a benchmark in the field of hepatology worldwide, with the best specialists in liver diseases and molecular biology. A clinic specialized in internal medicine, liver and digestive system in Madrid

© 2018 - 2026 FEHV Clinic. All rights reserved.  Privacy Policy.  Cookies Policy.  Legal Notice.